Skip to content

Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers

Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05279053
Enrollment
58
Registered
2022-03-15
Start date
2021-04-01
Completion date
2023-03-31
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoking, Sex

Brief summary

The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (estrogen and progesterone) in women. Glu was measured in the entire brain with special focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, all of which have been implicated in tobacco withdrawal, using an echo-planar spectroscopic imaging (EPSI) variant of magnetic resonance spectroscopy (MRS). Serum ovarian hormones (estrogen and progesterone) were measured for female participants to determine relationships between brain Glu and this hormone. Glu was be measured in smokers after overnight (\ 12 h) abstinence and after participants smoked the first cigarette of the day.

Detailed description

Glutamatergic signaling is dysregulated in addictions, including Tobacco Use Disorder (TUD) , and represents a promising target for smoking cessation therapies. In rodents, NMDA-type glutamate (Glu) receptor antagonists reduce nicotine-seeking behavior, whereas pre-treatment with NMDA-type and AMPA-type Glu receptor antagonists attenuates nicotine self-administration and nicotine-induced dopamine release. In humans, N-acetylcysteine, which regulates Glu via the cysteine-glutamate antiporter and glial Glu transporter, reduces cigarette smoking9 as well as cortical and subcortical levels of Glu itself, measured by magnetic resonance spectroscopy (MRS). These observations suggest that Glu, assayed by MRS, which is a safe and non-invasive in vivo metric, may aid in tracking regional effects of smoking and of anti-smoking interventions. Notably, evidence has been provided that Glu in the dorsal anterior cingulate cortex (dACC) is associated with smoking-related states, that Glx (the sum of Glu and its primary metabolite, glutamine, Gln) in dACC is higher in smokers than nonsmokers, and that Glx in the insula is higher after overnight abstinence from smoking than during satiety. Further, studies in smokers combining functional magnetic resonance imaging (fMRI) with MRS have linked dACC Glu with activation of the Default Mode Network during cue-induced cigarette craving, and demonstrated reduced dACC Glx and altered dACC-to-DMN connectivity following varenicline treatment. Prior MRS studies of smoking, however, have been limited by single-voxel techniques that sample single brain regions with restricted spatial-resolution and partial volume effects (i.e., including more than one tissue type in the acquisition voxel). We will exploit the echo-planar spectroscopic imaging (EPSI) variant of MRS in a high-density, anatomically broad assessment of how sex, acute smoking, and ovarian hormones affect brain Glu. Our pilot data indicate that dACC Glu is lower in smoking-abstinent women than men, and lower still in women with higher serum estrogen. After smoking, dACC Glu decreases in men but not in women. We will use EPSI to determine whether our dACC Glu pilot findings: 1) replicate at high spatial resolution; 2) pertain to the anterior insula and thalamus, which are also implicated in TUD, and 3) on an exploratory basis, pertain to other regions in the rest of the brain. To accomplish this, we will use a recently developed short echo-time (TE=20 ms) variant of 3D EPSI at 3-Tesla. With this state-of-the-art technique, we typically acquire high-quality spectra simultaneously from \ 80% of the brain at the very high spatial resolution of \ 0.4 cc. Short-TE, moreover, improves segregation of Glu from the overlapping Gln signal. We teste adult daily smokers (men and women) before and after their first cigarette of the day after \ 12 h abstinence. Serum estrogen and progesterone in women were assayed. We addressed two specific aims: Aim 1: Determine relationships between brain Glu, sex, and circulating ovarian hormones. Hypothesis 1a: Our single-voxel MRS finding that men have higher Glu in the dACC than women after overnight abstinence from smoking will be replicated with EPSI, and will extend to the anterior insula and thalamus. Hypothesis 1b: EPSI will replicate our preliminary finding that Glu in the dACC correlates negatively with serum estrogen (and possibly progesterone) in women, and will show similar relationships of ovarian hormones with the anterior insula and thalamus. Aim 2: Determine sex differences in acute effects of smoking on brain Glu. Hypothesis 2: The preliminary finding that Glu decreases after acute smoking in the dACC of men but increases or is unchanged in women will be replicated, and will extend to other brain regions. Ultimately, measurements of sex differences in Glu in specific brain regions, and how Glu changes with smoking and ovarian hormones, can define biomarkers that facilitate development of novel treatments and evaluate therapeutic response in men and women.

Interventions

BEHAVIORALAbstinence and Smoking

Participants came to the lab after overnight abstinence from smoking and smoked their first cigarette of the day.

Sponsors

University of California, Los Angeles
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. Self-identified as only male or female 2. Age 18-45 years (children \<18 years will be excluded due to low prevalence of conventional cigarette smoking; female participants \>45 years of age will be excluded to avoid effects of perimenopause and menopause in women; male participants \>45 years of age will be excluded as well to ensure that male and female groups are matched on age 3. English fluency demonstrated by verbal skills sufficient to participate in a conversation, including the ability to ask and answer questions at a level that assures adequate understanding of the study (a comprehension quiz will be given) 4. Right handedness (evaluated using the Edinburgh Inventory) 5. Generally in good health without cardiovascular, hepatic, renal, or autoimmune diseases, diabetes, or cancer 6. Must have smoked for ≥1 year 7. Must endorse inhaling while smoking 8. Must smoke ≥10 cigarettes per day 9. Must have expired CO \>10 ppm and urinary cotinine ≥100 ng/ml at screening/intake 10. Fulfillment of DSM-5 criteria for Tobacco Use Disorder

Exclusion criteria

1. Seeking treatment for nicotine dependence within 3 months of screening 2. Medical condition that may compromise safety (based on history, physical exam) 3. Neurological disorder that would compromise compliance and/or informed consent 4. Major psychiatric disorder (e.g., Major Depression, Schizophrenia, Bipolar Disorder) per DSM-5 MINI 5. Current drug use disorders other than Tobacco Use Disorder (as defined in DSM-5) 6. Recent use of cocaine, opiates, benzodiazepines, or amphetamines as shown by urine test at the screening or testing sessions 7. Smoke marijuana \>3X/week (self-report) or positive marijuana urine test on a scan day (positive at screening allowed) 8. Use of tobacco in forms other than cigarettes (e.g., snuff, chewing tobacco, e-cigarettes) \>10 days in the month before screening 9. Preference for menthol cigarettes, given sex differences in the effect of menthol on the rate of nicotine entry into the brain 10. Pregnancy or nursing 11. Presence in the body of metal that would compromise safety during MRI 12. Claustrophobia 13. Any other condition that would compromise safety

Design outcomes

Primary

MeasureTime frameDescription
Glutamate in the Dorsal Anterior Cingulate CortexMeasured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.Glutamate levels, as measured using MRS, in the dorsal anterior cingulate cortex.
Glutamate in the InsulaMeasured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.Glutamate levels, as measured using MRS, in the insula.
Glutamate in Whole Brain (Gray Matter Plus White Matter).Measured before and after smoking a cigarette by both groups (men and women). Group means below reflect overall group means averaged across time points as reported from descriptive statistics in the Generalized Linear Mixed Model.Glutamate measured using the MRS echoplanar spectroscopic imaging in abstinent smokers.
Serum EstrogenSampling performed on same day as MRS (before smoking).Estrogen concentration measured in serum from blood samples drawn prior to MRS (women only).

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOREdythe London, PhD

University of California, Los Angeles

Participant flow

Recruitment details

Recruitment occurred from April 1, 2021 through March 31, 2023. Potential subjects were self-identified as smokers or nonsmokers, and recruited via online and print media, (e.g. Craigslist). Flyers were posted in the UCLA campus. Advertisements are designed to attract smokers interested in participation in research on smoking in exchange for monetary compensation.

Pre-assignment details

Of 58 participants who gave informed consent, 49 completed assessments and provided usable data. The others had issues in attrition or quality control of MRS measurements.

Baseline characteristics

Characteristic
Age, Continuous33 years
STANDARD_DEVIATION 6
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
17 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
Glutamate in dorsal anterior cingulate7.52 Institutional Units
STANDARD_DEVIATION 1.65
Glutamate in the insula7.38 Institutional Units
STANDARD_DEVIATION 1.18
Glutamate in whole brain5.52 Institutional Units
STANDARD_DEVIATION 1.03
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
3 Participants
Race (NIH/OMB)
Black or African American
11 Participants
Race (NIH/OMB)
More than one race
5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
Race (NIH/OMB)
White
26 Participants
Region of Enrollment
United States
58 Participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 360 / 22
other
Total, other adverse events
0 / 360 / 22
serious
Total, serious adverse events
0 / 360 / 22

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026